Incyte Genomics, Inc. (INCY) Posts Narrower than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $98.22 -0.78%
Revenue Growth %: +29.4%
Financial Fact:
Research and development: 143.18M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +29.4%
Financial Fact:
Research and development: 143.18M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q3 loss of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.54 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Sonoma Pharmaceuticals (SNOA) Misses Q4 EPS by 33c
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
